BlackRock Advisors’s KalVista Pharmaceuticals KALV Stock Holding History

BlackRock Advisors’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$2K	Hold	258	–	–	﹤0.01%	3677
2016 Q3	$2K	Hold	258	–	–	﹤0.01%	3684
2016 Q2	$2K	Sell	258 -234	-48%	-$2.71K	﹤0.01%	3713
2016 Q1	$4K	Hold	492	–	–	﹤0.01%	3689
2015 Q4	$25K	Sell	492 -204	-29%	-$10.7K	﹤0.01%	3428
2015 Q3	$35K	Buy	696 +99	+17%	+$8.44K	﹤0.01%	3384
2015 Q2	$60K	Buy	+597	New	+$59.2K	﹤0.01%	3303

Other funds holding KALV

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

IBT

International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Quadrant Glendale, California $18M AUM 24.2% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

BlackRock Advisors's KALV Position: Q4 2016 in Review

BlackRock Advisors held its KalVista Pharmaceuticals (KALV) position steady in Q4 2016 at 258 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #3677.

BlackRock Advisors first reported a position in KALV in Q2 2015 and has held it in 7 quarters since. The position peaked at $60K in Q2 2015. 20 funds tracked by Wall St. Rank hold KALV as of Q4 2016.

BlackRock Advisors held 258 shares of KalVista Pharmaceuticals worth $2K as of Q4 2016.
BlackRock Advisors left its KalVista Pharmaceuticals share count unchanged in Q4 2016.
KalVista Pharmaceuticals made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #3677 holding.
BlackRock Advisors first reported a position in KalVista Pharmaceuticals in Q2 2015 and has held it in 7 quarters since.
BlackRock Advisors's KalVista Pharmaceuticals position peaked at $60K in Q2 2015.
20 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.